OncoMatch/Clinical Trials/NCT05761366

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Is NCT05761366 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Al18F-PSMA-BCH PET/CT for malignancy.

Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05761366Data as of May 2026

Treatment: Al18F-PSMA-BCH PET/CT — In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Required: FOLH1 positive-expressing

PSMA positive-expressing tumors

Prior therapy

Cannot have received: experimental drug or device

Received experimental drug or device within 1 month

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify